摘要
目的:观察脂必泰胶囊联合匹伐他汀对冠心病患者血脂水平的影响.方法:选择2018年3月～2021年2月间我院收治的180例冠心病患者,按照随机数字表法分为匹伐他汀组(90例)和联合治疗组(90例,脂必泰胶囊联合匹伐他汀治疗),两组均治疗8周.观察两组临床疗效、治疗前后血脂、炎症因子水平变化及不良反应发生情况.结果:联合治疗组的临床总有效率显著高于匹伐他汀组(94.44％比80.00％,P=0.001).治疗后,与匹伐他汀组比较,联合治疗组血清总胆固醇(TC)[(4.39±0.71)mmol/L比(2.86±0.56)mmol/L]、甘油三酯(TG)[(2.28±0.43)mmol/L 比(1.46±0.39)mmol/L]、低密度脂蛋白胆固醇(LDL-C)[(2.93±0.50)mmol/L 比(1.84±0.52)mmol/L]、脂蛋白(a)[(124.57±11.37)mmol/L 比(85.83±11.96)mmol/L]水平及白介素-6(IL-6)[(21.28±3.64)pg/ml 比(12.39±2.08)pg/ml]、高迁移率族蛋白 B1(HMGB1)[(3.84±0.98)μg/L比(1.28±0.79)μg/L]、肿瘤坏死因子-α(TNF-α)[(4.06±0.62)ng/ml 比(2.39±0.48)ng/ml]水平均显著降低,高密度脂蛋白胆固醇(HDL-C)[(1.89±0.26)mmol/L比(2.63±0.31)mmol/L]水平显著升高(P均=0.001).两组不良反应发生率对比无统计学差异(P=0.600).结论:脂必泰胶囊联合匹伐他汀治疗冠心病患者,可有效调节血脂,降低炎症因子水平,安全有效.
Abstract
Objective:To observe the effect of Zhibitai capsule combined with pitavastatin on blood lipid levels in pa-tients with coronary heart disease(CHD).Methods:A total of 180 CHD patients who were treated in our hospital from Mar 2018 to Feb 2021 were selected.According to random number table method,they were divided into pita-vastatin group(n=90)and combined treatment group(n=90,received Zhibitai capsule combined with pitavasta-tin),and both groups were treated for eight weeks.Clinical therapeutic effect,levels of blood lipids and inflamma-tory factors before and after treatment,and incidence of adverse reactions were observed and compared between two groups.Results:Total effective rate of combined treatment group was significantly higher than that of pitavas-tatin group(94.44％vs.80.00％,P=0.001).Compared with pitavastatin group after treatment,there were signif-icant reductions in serum levels of total cholesterol(TC)[(4.39±0.71)mmol/L vs.(2.86±0.56)mmol/L],tri-glyceride(TG)[(2.28±0.43)mmol/L vs.(1.46±0.39)mmol/L],low density lipoprotein cholesterol(LDL-C)[(2.93±0.50)mmol/L vs.(1.84±0.52)mmol/L],lipoprotein(a)[(124.57±11.37)mmol/L vs.(85.83± 11.96)mmol/L],interleukin-6(IL-6)[(21.28±3.64)pg/mlvs.(12.39±2.08)pg/ml],high mobility group box-1 protein B1(HMGB1)[(3.84±0.98)μg/L vs.(1.28±0.79)μg/L],tumor necrosis factor-α(TNF-α)[(4.06±0.62)ng/ml vs.(2.39±0.48)ng/ml],and significant rise in level of high density lipoprotein cholesterol(HDL-C)[(1.89±0.26)mmol/L vs.(2.63±0.31)mmol/L]in combined treatment group,P=0.001 all.There was no significant difference in incidence rate of adverse reactions between two groups,P=0.600.Conclu-sion:Zhibitai capsule combined with pitavastatin can effectively regulate blood lipids,reduce the levels of inflamma-tory factors in patients with coronary heart disease,which is safe and effective.
维普
万方数据